Ignite Creation Date:
2024-05-06 @ 3:09 AM
Last Modification Date:
2024-10-26 @ 11:29 AM
Study NCT ID:
NCT02213744
Status:
TERMINATED
Last Update Posted:
2017-01-06
First Post:
2014-08-06
Brief Title:
MM-302 Plus Trastuzumab vs Chemotherapy of Physicians Choice Plus Trastuzumab in HER2-Positive Locally AdvancedMetastatic Breast Cancer Patients
Sponsor:
Merrimack Pharmaceuticals
Organization:
Merrimack Pharmaceuticals
Organization Data
Organization:
Merrimack Pharmaceuticals
Class:
INDUSTRY
Study ID:
MM-302-02-02-03
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Merrimack Pharmaceuticals
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None